Form 4: LENZ CEO buys 28,089 shares at $8.95 average

LENZ Therapeutics CEO Evert B. Schimmelpennink purchased 28,089 shares at a weighted average $8.9505, lifting his direct holdings to 77,289 shares.

Summary

• Evert B. Schimmelpennink (President, CEO, Secretary, and Director of LENZ Therapeutics, Inc.) executed an open‑market purchase of 28,089 common shares on 03/27/2026.
• The weighted average purchase price was $8.9505, with trades executed between $8.80 and $9.25.
• Post-transaction, Schimmelpennink directly owns 77,289 shares of LENZ common stock.
• The transaction was coded “P” (open‑market or private purchase of non-derivative security) and reported on Form 4 as a change in beneficial ownership.
• The filing was signed by Attorney-in-Fact Daniel R. Chevallard on 03/30/2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this insider open-market purchase by the CEO as a modestly positive governance and alignment signal, though it does not change the fundamental outlook.

Positives

• Insider open-market purchase by the CEO/President/Secretary/Director signals potential management confidence.
• Direct ownership increased to 77,289 shares, improving alignment with shareholders.
• Purchase occurred in a transparent price range of $8.80–$9.25 (weighted average $8.9505).

Negatives

• No disclosure of the rationale behind the purchase.
• No new financial, operational, or strategic information accompanies the transaction.
• Single insider transaction; no indication of broader insider buying activity.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes that open‑market insider purchases by senior executives in biotech are generally interpreted as a modestly positive signal of confidence but do not provide incremental information on clinical, regulatory, or financial performance.

Comparison to Industry Standards

• Not applicable: This is an insider transaction disclosure without operational or financial results to benchmark against industry peers.

Stakeholder Impact

• Shareholders may view the CEO’s purchase as a sign of confidence and better alignment.
• No dilution to existing shareholders since shares were acquired on the open market.
• No immediate impact on customers, suppliers, or employees indicated.

Key Dates

Recommendation

A CEO open-market purchase is a constructive signal but, in isolation and without additional operational or financial updates, it does not justify a change in investment stance. Maintain hold pending catalysts or fundamentals.

Keywords

LENZ Therapeutics, LENZ, Form 4, insider buying, Evert B. Schimmelpennink, CEO purchase, open market transaction, beneficial ownership, biotech